Table 2.
Estimated national prevalence of sleep disturbance and sleep-related impairment, by AD severity and race.
| No sleep disturbance | Sleep disturbance | Severe sleep disturbance | No sleep-related impairment | Sleep-related impairment | Severe sleep-related impairment | |
|---|---|---|---|---|---|---|
| POEM severity of AD | ||||||
| Mild | 1,246,572 (40.3%) | 636,118 (21.0%) | 1,143,962 (37.8%) | 1,456,317 (48.1%) | 860,844 (28.4%) | 709,490 (23.4%) |
| Moderate | 262,342 (20.6%) | 309,683 (24.3%) | 704,275 (55.2%) | 312,222 (24.5%) | 267,908 (21.0%) | 696,170 (54.5%) |
| Severe | 30,920 (8.8%) | 25,359 (7.2%) | 296,909 (84.1%) | 3,8335 (10.9%) | 28,747 (8.1%) | 286,106 (81.0%) |
| Race | ||||||
| White | 970,961 (34.3%) | 336,321 (11.9%) | 1,520,678 (53.8%) | 1,234,209 (43.6%) | 54,1172 (19.1%) | 1,052,580 (37.2%) |
| Black | 289,252 (23.7%) | 512,547 (42.0%) | 419,385 (34.3%) | 25,8677 (21.2%) | 50,4947 (41.3%) | 457,560 (37.5%) |
| Other | 279,621 (46.1%) | 122,292 (20.1%) | 205,083 (33.8%) | 313,989 (51.7%) | 111,380 (18.3%) | 181,626 (29.9%) |
| Total * | 1,539,834 (33.1%) | 971,160 (20.9%) | 2,145,145 (46.1%) | 1,806,874 (38.8%) | 1,157,499 (24.9%) | 1,691,766 (36.3%) |
*
Reflects total number and percentage of US population with atopic dermatitis that experience sleep disturbance or sleep-related impairment respectively.